Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target at $42.89
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock […]
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock […]
